Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Cha

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Human Vaccines & Immunotherapeutics|November 16, 2012
Plasmid IL-12 electroporation in melanomaEdward Cha, Adil Daud
Current Opinion in Molecular Therapeutics|February 9, 2010
Therapeutic vaccines for prostate cancerEdward Cha, Lawrence Fong
Oncoimmunology|April 11, 2018
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patientsEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Immunotherapy for prostate cancer: biology and therapeutic approachesEdward Cha, Lawrence Fong
Cancer Medicine|May 2, 2013
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Edward Cha, Eric J Small
Seminars in Oncology|May 13, 2015
PD-L1 inhibition with MPDL3280A for solid tumorsEdward Cha, Jeffrey Wallin, Marcin Kowanetz
Nature Reviews. Cancer|March 2, 2012
Unmasking the immune recognition of prostate cancer with CTLA4 blockadeSerena S Kwek, Edward Cha, Lawrence Fong
Cancer Chemotherapy and Pharmacology|January 14, 2016
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancerMark Stroh, Michelle Green, Edward Cha, et al.
Science Translational Medicine|May 30, 2014
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsEdward Cha, Mark Klinger, Yafei Hou, et al.
Clinical Lung Cancer|August 30, 2021
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b TrialDeborah J Wong, Todd M Bauer, Michael S Gordon, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|November 16, 2012
Plasmid IL-12 electroporation in melanomaEdward Cha, Adil Daud
Current Opinion in Molecular Therapeutics|February 9, 2010
Therapeutic vaccines for prostate cancerEdward Cha, Lawrence Fong
Oncoimmunology|April 11, 2018
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patientsEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Immunotherapy for prostate cancer: biology and therapeutic approachesEdward Cha, Lawrence Fong
Cancer Medicine|May 2, 2013
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Edward Cha, Eric J Small
Seminars in Oncology|May 13, 2015
PD-L1 inhibition with MPDL3280A for solid tumorsEdward Cha, Jeffrey Wallin, Marcin Kowanetz
Nature Reviews. Cancer|March 2, 2012
Unmasking the immune recognition of prostate cancer with CTLA4 blockadeSerena S Kwek, Edward Cha, Lawrence Fong
Cancer Chemotherapy and Pharmacology|January 14, 2016
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancerMark Stroh, Michelle Green, Edward Cha, et al.
Science Translational Medicine|May 30, 2014
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsEdward Cha, Mark Klinger, Yafei Hou, et al.
Clinical Lung Cancer|August 30, 2021
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b TrialDeborah J Wong, Todd M Bauer, Michael S Gordon, et al.
Pageof 3